Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Anuj Jain, Bhushan Mundada, Monica Jain, Meghana Nahata
Reconstruction of maxillary defects can be carried out by a variety of treatment modalities. The choice of modality depends on numerous factors including the size and extent of the defect, patient factors and existing comorbidities. One of the various options is reconstruction and rehabilitation using a fixed prosthesis supported over zygomatic implant. In maxillectomy cases, zygomatic implant can be used to improve the retention of the obturator prosthesis as loss of alveolar bone makes it impossible to use conventional endosseous implants...
April 10, 2024: Journal of Oral Implantology
#22
JOURNAL ARTICLE
Xiaoying Zhang, Lingfeng Zhang, Yun Li, Na Wang, Yicheng Zhang
BACKGROUND: Timely diagnosis and appropriate antifungal therapy are critical for improving the prognosis of patients with invasive fungal disease (IFD) after hematopoietic stem cell transplantation (HSCT). We evaluated the performance of metagenomic next-generation sequencing (mNGS) and conventional microbiological testing (CMT), as well as the diagnosis, therapeutic management, and outcomes of IFD after HSCT. METHODS: We retrospectively studied 189 patients who underwent HSCT and were considered at risk for IFD...
2024: Frontiers in Cellular and Infection Microbiology
#23
JOURNAL ARTICLE
Rajesh Kumar Yadav, Saurabh Karmakar, Abdul Raouf Wani, Vinay V
Pulmonary mucormycosis is a rare but highly lethal fungal infection, usually affecting immunocompromised patients. Pulmonary mucormycosis was also a critical problem that complicated the later part of the clinical course of COVID-19 in India. Early diagnosis of the disease, combined with aggressive treatment, is crucial for patient survival. Fibreoptic bronchoscopy is a useful procedure for diagnosis of pulmonary mucormycosis, but image-guided percutaneous biopsy efficiently samples lesions abutting the chest wall...
April 2024: Indian Journal of Tuberculosis
#24
JOURNAL ARTICLE
Elisavet Stavropoulou, Anne Huguenin, Giorgia Caruana, Onya Opota, Nancy Perrottet, Dominique S Blanc, Bruno Grandbastien, Laurence Senn, Pierre-Yves Bochud, Frederic Lamoth
AIMS OF THE STUDY: Invasive mould infections are life-threatening complications in patients with haematologic cancer and chemotherapy-induced neutropenia. While invasive aspergillosis represents the main cause of invasive mould infections, non-Aspergillus mould infections, such as mucormycosis, are increasingly reported. Consequently, their local epidemiology should be closely monitored. The aim of this study was to investigate the causes of an increased incidence of non-Aspergillus mould infections in the onco-haematology unit of a Swiss tertiary care hospital...
March 26, 2024: Swiss Medical Weekly
#25
Hatan Mortada, Razan Albrahim, Saad Alrobaiea, Moinuddin Ahmad, Elfayad Hamad A Abdelraheem, Muath Hakami
Mucormycosis hand infection in poorly controlled diabetic presented as rapidly progressive swelling, redness, pain, and necrosis unresponsive to antibiotics. Prompt diagnosis and aggressive surgery, antifungals, and diabetes management were critical, highlighting the need for early recognition and treatment of mucormycosis in diabetics.
2024: Case Reports in Plastic Surgery & Hand Surgery
#26
JOURNAL ARTICLE
Prahlada Nayaka Basavanthappa, C Narayana Murthy, Sonam S Nandyal, T M Radhika
Coronavirus disease 2019 attributed to severe acute respiratory syndrome has been implicated with life threatening opportunistic infections like mucormycosis. COVID-19 is a hyperferritinemic syndrome and emerging data project the role of iron in the susceptibility and pathogenesis of mucormycosis but whether high ferritin is an indicator of severity of mucormycosis is debated. The study aimed to determine the relationship between serum ferritin levels and the extent of involvement of COVID-19 associated mucormycosis...
April 2024: Indian Journal of Otolaryngology and Head and Neck Surgery
#27
JOURNAL ARTICLE
Anchal Kumar Jain, Yamini Gupta, Jagram Verma, Surbhi Godha, Indra Prakash Prajapati
Mucormycosis is an aggressive, fatal fungal infection. The fungal organisms are ubiquitous and easily affect immunocompromised patients. The main aim of this article is to emphasize over the knowledge of different diagnostic methods (diagnostic nasal endoscopy, ct/ contrast mri pns + orbit + brain, Wet KOH mount), the importance of practising an aggressive surgical resection, medical treatments (liposomal amphotericin B, amphotericin gel, tablet posaconazole, nasal douching, retrorbital amphotericin injection), suction cleaning and regular follow up of the patient after surgical management...
April 2024: Indian Journal of Otolaryngology and Head and Neck Surgery
#28
JOURNAL ARTICLE
Anshul Sharma, Surbhi Godha, Jagram Verma, Lokesh Bhalot, Yamini Gupta, R K Mundra
Rhinocerebralmucormycosis, is a progressive fungal invasion of a hard palate, paranasal sinuses, orbit, and brain. Post covid the huge number of mucor cases reported in our institute. To combat them a uniform assessment scale was needed as multiple healthcare workers were involved. Thus, a novel linear grading system on nasal endoscopy was developed for the early management of patients to prevent morbidity and mortality. A Prospective study of 650 patients in Epidemic duration from April to June 2021 in a tertiary health center, Central India...
April 2024: Indian Journal of Otolaryngology and Head and Neck Surgery
#29
JOURNAL ARTICLE
Kamala S Devi, Abilasha R, Suvarna Kizhakkoottu
Introduction Most fungal infections are responsive to antifungal therapy. However, failure to diagnose the same can significantly affect the quality of lives of patients. Timely identification of fungal infections and their association with varied demographic and clinical parameters will help in improving the prognosis of the patient. The present study aims to evaluate the prevalence of fungal infections among various age groups and genders and also to evaluate the association of fungal infections with demographic parameters...
March 2024: Curēus
#30
REVIEW
Sunita Panda, Mahesh Chandra Sahu, Jyotirmayee Turuk, Sanghamitra Pati
Mucormycosis is the third most frequent invasive mycosis, following candidiasis and aspergillosis. It is frequently neglected due to its rare occurrence; but recently attend the status of notifiable disease due to its higher incidence in both developed and developing nations. India has received global notice since its estimated instances were greater than the global estimated figures. Mucormycosis has several clinical manifestations, including rhino-orbital-cerebral (ROCM), pulmonary, gastrointestinal, cutaneous, renal, and diffuse Mucormycosis...
April 1, 2024: Brazilian Journal of Microbiology: [publication of the Brazilian Society for Microbiology]
#31
Abdisalam Abdullahi Yusuf, Ismail Gedi Ibrahim, Ibrahim Mohamed Hirsi, Ali Adali, Yonis Yusuf Hassan, Mehmet Zeki Yasar, Ismail Mohamoud Abdullahi, Mohamed Sheikh Hassan
Mucormycosis is a potentially fatal condition with a high mortality rate, particularly when there is extra nasal involvement, and it is rare for patients with fungal brain disease to survive. It mostly affects patients who are metabolically or immunologically compromised, which constitutes one of the three classical stages of the progression of Rhino-Orbito-Cerebral Mucormycosis (ROCM). Stage I: infection of the nasal mucosa and paranasal sinuses; Stage II: orbital involvement; Stage III: cerebral involvement...
2024: International Medical Case Reports Journal
#32
JOURNAL ARTICLE
Rizwan Suliankatchi Abdulkader, Manickam Ponnaiah, Tarun Bhatnagar, Devika S, Amanda G A Rozario, Gayathri K, Malu Mohan, Michaelraj E, Divya Saravanakumar, Aditya Moorthy, Amit Kumar Tyagi, Bhagirathsinh D Parmar, K Devaraja, Gaurav Medikeri, Jutika Ojah, Kajal Srivastava, Karthikeyan K, Nandini Das, Niharika B, Parul Sharma, Pradipta Kumar Parida, Prasanna Kumar Saravanam, Praveen Kulkarni, Priya S, Pushpa Patil S, Rahul Kumar Bagla, Ramesh D, Renuka S Melkundi, Satish S Satpute, Seetharaman Narayanan, Shubhashri Jahagirdar, Simmi Dube, Sunil Kumar Panigrahi, Surendra Babu D, Vaibhav Saini, Rita Singh Saxena, Abhinav Srivastava, Achyut Chandra Baishya, Ajai Garg, Amit Kumar Mishra, Anjan Jyoti Talukdar, Ankita Kankaria, Arathi Karat, Arul Sundaresh Kumar, Ashi Chug, Ashok Vankundre, Balakrishnan Ramaswamy, Bharathi Mb, Bhargav R Jadav, Muthuswamy Dhiwakar, Girija Ghate, Hardik V Shah, Ipsita Saha, Kavya Sivapuram, Krupal J Joshi, Mahendra Singh, Mukesh Chand Bairwa, Divya K, Karthikeyan K, Muthurajesh E, Navneh Samagh, Nethra Dinakaran, Nikhil Gupta, Nitin Gupta, Nitin M Nagarkar, Nitin Solanki, Prasan Kumar Panda, Prithvi Bachalli, Raghunath Shanbag, Rajashri Patil, Rajesh Kumar A, Rakesh Narayan Patil, Ramanikanth Thookkanaickenpalayam Vijayaraghavan, Ramesh Hanumantappa, Rathinavel A, Saleel Kumar Mandal, Sanjay Pandharinath Kishve, Sara Varghese Thomas, Saurav Sarkar, Shalini Thakur, Siddaram Patil, Somu Lakshmanan, Srinivas D Rao, Sumathi V, Tulasi Nayak, Umesh R Dixit, Unnikrishnan B, Varsha Backiavathy, Vijendra Shenoy, Vinay Kumar Hallur, Aparna Bhatnagar, Manoj V Murhekar
In India, the incidence of mucormycosis reached high levels during 2021-2022, coinciding with the COVID-19 pandemic. In response to this, we established a multicentric ambispective cohort of patients hospitalised with mucormycosis across India. In this paper, we report their baseline profile, clinical characteristics and outcomes at discharge. Patients hospitalized for mucormycosis during March-July 2021 were included. Mucormycosis was diagnosed based on mycological confirmation on direct microscopy (KOH/Calcofluor white stain), culture, histopathology, or supportive evidence from endoscopy or imaging...
2024: Mycology
#33
JOURNAL ARTICLE
Teclegiorgis Gebremariam, Sondus Alkhazraji, Yiyou Gu, Laura K Najvar, Katyna Borroto-Esoda, Thomas F Patterson, Scott G Filler, Nathan P Wiederhold, Ashraf S Ibrahim
Ibrexafungerp (formerly SCY-078) is the first member of the triterpenoid class that prevents the synthesis of the fungal cell wall polymer β-(1,3)-D-glucan by inhibiting the enzyme glucan synthase. We evaluated the in vivo efficacy of ibrexafungerp against pulmonary mucormycosis using an established murine model. Neutropenic mice were intratracheally infected with either Rhizopus delemar or Mucor circinelloides . Treatment with placebo (diluent control), ibrexafungerp (30 mg/kg, PO BID), liposomal amphotericin B (LAMB 10 mg/kg IV QD), posaconazole (PSC 30 mg/kg PO QD), or a combination of ibrexafungerp plus LAMB or ibrexafungerp plus PSC began 16 h post-infection and continued for 7 days for ibrexafungerp or PSC and through day 4 for LAMB...
April 1, 2024: Antimicrobial Agents and Chemotherapy
#34
JOURNAL ARTICLE
Mragnayani Pandey, Immaculata Xess, Janya Sachdev, Neha Sharad, Sonakshi Gupta, Gagandeep Singh, Renu Kumari Yadav, Bhaskar Rana, Stephen Raj, M Nizam Ahmad, Neha Nityadarshini, Upendra Baitha, Manish Soneja, Shalimar, Bindu Prakash, Kapil Sikka, Purva Mathur, Viveka P Jyotsna, Rakesh Kumar, Naveet Wig, Sudesh Gourav, Ashutosh Biswas, Alok Thakar
INTRODUCTION: Invasive mould infections (IMIs) are a leading cause of death in patients with compromised immune systems. Proven invasive mould infection requires detection of a fungus by histopathological analysis of a biopsied specimen, sterile culture, or fungal DNA amplification by PCR in tissue. However, the clinical performance of a PCR assay on blood samples taken from patients suspected of invasive mould disease has not been fully evaluated, particularly for the differential diagnosis of invasive aspergillosis (IA) and invasive Mucormycosis (IM)...
March 28, 2024: Journal of Infection
#35
JOURNAL ARTICLE
Du He, Zhu Wang
No abstract text is available yet for this article.
March 29, 2024: Journal of Gastrointestinal and Liver Diseases: JGLD
#36
JOURNAL ARTICLE
Zhiqiang Song, Yang Wang, Ping Liu, Yuke Geng, Na Liu, Jie Chen, Jianmin Yang
Chimeric antigen receptor T-cell (CAR-T) therapy has achieved durable response in patients with hematological malignancies, however, therapy-associated multisystem toxicities are commonly observed. Here, we systematically analyzed CAR-T-related gastrointestinal adverse events (GAEs) using the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) between January 2017 and December 2021. Disproportionality analyses were performed using reporting odds ratios (ROR) and information component (IC)...
March 28, 2024: Cancer Gene Therapy
#37
Trung Minh Nguyen, Eva Amenta, Lynne Chapman, Sarvari Yellapragada, Bhuvaneswari Krishnan, Jonathan Lim, Richard J Hamill
The use of ibrutinib, a Bruton tyrosine kinase inhibitor, has been associated with invasive fungal infections (IFIs). We describe a case of Apophysomyces infection associated with long-term use of ibrutinib for the treatment of chronic lymphocytic leukemia as well as perform a literature review of Mucormycosis infections in patients on ibrutinib. Our review found that the onset of IFI can occur within months to years of starting tyrosine kinase inhibitors. These reports provide a more complete picture of the risk of IFI while patients are on ibrutinib...
2024: Therapeutic Advances in Infectious Disease
#38
JOURNAL ARTICLE
Anne-Pauline Bellange, Gbaguidi-Haore Houssein, Ana Berceanu, Laura Gouzien, Chaima El Machhour, Damien Bichard, Fanny Lanternier, Emeline Scherer, Laurence Millon
Our objective was to determine whether the twice-weekly screening of high-risk hematology patients by Mucorales qPCR on serum affects the prognosis of mucormycosis. Results from all serum Mucorales qPCR tests performed on patients from the hematology unit from January 2017 to December 2022 were analyzed. Patients with positive results were classified as having proven, probable or 'PCR-only' mucormycosis. One-month mortality for the local cohort was compared with that of a national cohort of cases of mucormycosis collected by the French surveillance network for invasive fungal disease ('Réseau de surveillances des infections fongiques invasives en France' (RESSIF)) from 2012 to 2018...
March 26, 2024: Medical Mycology
#39
JOURNAL ARTICLE
Khoa N Nguyen, Lindsey M Freeman, Timothy H Ung, Steven Ojemann, Fabio Grassia
BACKGROUND: Isolated cerebral mucormycosis is rare in immunocompetent adults and is only sparsely reported to be associated with obstructive hydrocephalus. OBSERVATIONS: Here, the authors report a case of obstructive hydrocephalus secondary to central nervous system mucormycosis without other systems or rhino-orbital involvement and its technical surgical management. A 23-year-old, incarcerated, immunocompetent patient with history of intravenous (IV) drug use presented with syncope...
March 25, 2024: J Neurosurg Case Lessons
#40
JOURNAL ARTICLE
Veena K Singh, Ansarul Haq, Sarsij Sharma, Anupama Kumari
Aim of the Study Mucormycosis is a rare invasive and fatal fungal infection and its resurgence in coronavirus disease 2019 (COVID-19) patients has been a matter of grave concern. It is essentially a medical disease, but surgical debridement of necrotic tissues is of paramount importance leading to severe craniofacial deformities. In this case series, we present our experience with the feasibility of early reconstruction after surgical debridement. Case Series As a Dedicated COVID Center (DCH), the institute received the largest population of COVID-19 mucormycosis patients from the entire eastern region of the country between May 2021 and August 2021...
January 2024: Surgery Journal
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
